Stockwatch: Intercepting The Falling Knives Of NASH
Misperceptions Of Safety And Efficacy Plus The Invalidation Of A Surrogate Marker Hit Intercept
Executive Summary
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
You may also be interested in...
Stock Watch: Tales Of Stock Price Overreactions
Two clinical trial announcements in the same NASH indication separated by almost nine years had very similar stock price reactions despite the known unknowns of NASH remaining unknown.
NASH Backlash: Intercept Delay Raises Questions
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
No longer quiet NGM Bio unveils Phase II data at EASL showing rapid and significant reductions of hepatic fat, while Bristol announces a partnership to produce a non-invasive diagnostic for NASH and presents promising Phase II data for its FGF21 analogue.